



Contacts:

David Waldman or Justyna Gudaszewska
Crescendo Communications Europe Sp. z.o.o
Email: mmd@crescendo-ir.com
Tel: (+48 71) 79 11 551

Milestone Scientific, Licensor of Milestone Medical's Computer-Controlled Injection and Drug Delivery Technology, Commences Trading on the NYSE MKT

LIVINGSTON, NJ, June 9, 2015, Milestone Medical (WAR:MMD) today announced that Milestone Scientific, licensor of Milestone Medical's computer-controlled injection and drug delivery technology, has commenced trading of its common shares on the NYSE MKT, which is subject to continued satisfaction of listing requirements. Milestone Scientific continues to trade under the symbol "MLSS."

Leonard Osser, CEO of Milestone Medical commented, "The listing of Milestone Scientific's common shares on the NYSE MKT illustrates both the commercial progress and reception to the core technology in the U.S. capital markets. With Milestone Scientific owning 49.9% of Milestone Medical, its listing on the NYSE MKT should provide both Milestone Scientific and Milestone Medical with increased exposure within the investment community. This move aligns with our own plans to uplist from the NewConnect market to Main Market of Warsaw Stock Exchange this year."

NYSE MKT is a fully integrated trading venue within the NYSE community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE community.

About Milestone Scientific

Milestone Scientific Inc. (MLSS) is a medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory marketing clearance in the U.S. and has recently received CE marketing clearance for both instruments in the European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.